Zhejiang Medicine (600216.SH): Plans to invest 157 million yuan to jointly invest in Xiamen Huaben Qihang Equity Investment Partnership

NightAirdropper · 2026-03-11T05:05:08+00:00

Zhejiang Medicine and its partners signed an agreement to invest 320 million yuan in Xiamen Huaben Qihang Equity Investment Partnership. The company became a limited partner with 157 million yuan, focusing on emerging industries such as biomedicine, with an investment ratio of no less than 60%.

NightAirdropper

2026-03-11 05:05:08

Abstract generation in progress

Gelonghui, March 9 — Zhejiang Medicine (600216.SH) announced that on March 9, 2026, the company and the general partner Xiamen Huaben Contemporary Venture Capital Management Co., Ltd., limited partners Cai Xiaoyang, Yu Fengjia, and Yu Zhangxing signed the “Partnership Agreement of Xiamen Huaben Qihang Equity Investment Partnership (Limited Partnership),” jointly investing in Xiamen Huaben Qihang Equity Investment Partnership (Limited Partnership). The total committed capital of the partnership is 320 million yuan, with the company as a limited partner contributing 157 million yuan, accounting for 49.06% of the total committed capital.

The partnership is managed by Xiamen Huaben Contemporary Venture Capital Management Co., Ltd., serving as the general partner, executive partner, and fund manager. The fund’s investments mainly focus on strategic emerging industries such as biomedicine, with no less than 60% of the fund’s scale invested in these sectors.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.